CMO expands drug recall over bacterial contamination concerns

CMO PharmaTech, whose constipation drug has been tied to a growing outbreak of bacterial infections in hospitals, has broadened its recall to 30 products in case others were also contaminated.

In a release distributed by the FDA today, the Davie, FL-based company said it was recalling all of its liquid products manufactured in the 9 months between Oct. 20, 2015 and July 15, 2016 as a precautionary measure due to the risk they might be contaminated by Burkholderia cepacia.

The FDA in a separate release identified 10 liquid drug products and 20 dietary supplements, including Liquid Vitamin C and several Pedia products.  

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Last month, PharmaTech recalled all lots of its Diocto Liquid product after the FDA said it had confirmed that the docusate sodium solution had been contaminated with Burkholderia cepacia, a bacterium linked to an outbreak in hospitals in 5 states. In an update on the outbreak July 26, the Centers for Disease Control said it has now documented 58 cases of infections from 8 states.

The outbreak was initially seen in ventilated patients without cystic fibrosis who were being treated in intensive care units but has since been tied to other patients. The FDA warned that serious infections could be life-threatening in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis.

- here’s the FDA announcement
- here's the CDC update
- here's the list of recalled products 

Related Articles: 
CMO recalls constipation drug tied to bacterial infections reported in 5 states


Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.